分子靶向药物索拉非尼在甲状腺癌的应用进展

Application development of the molecular targeted therapy sorafenib for thyroid carcinoma

部分难治性甲状腺癌和特殊病理类型的甲状腺癌缺少有效的治疗方法,预后较差。国内外多个医疗中心已进行过索拉非尼治疗甲状腺癌的临床研究,多数已进入2、3期临床试验,包括晚期分化型甲状腺癌、髓样癌、未分化癌等,临床试验证实索拉非尼可有效提高甲状腺癌患者无进展生存期(PFS)、客观缓解率(OR),但对总生存期(OS)的影响尚无定论。本文将围绕索拉非尼的作用机制、治疗效果及不良反应,讨论索拉非尼用于治疗甲状腺癌的进展。

Part of radioactive iodine-refractory and special pathological types of thyroid cancer lacks effective treatment, leading to poor outcomes. Clinical studies of sorafenib treatment for thyroid cancer have been subjected to many domestic and international medical centers, most of which have entered the phase 2 and 3 clinical trials, including advanced differentiated thyroid cancer, medullary carcinoma, and anaplastic carcinoma. In some clinical trials, sorafenib has improved median progression-free survival （PFS） , objective response （OR） rate, but the impact on overall survival （OS） is inconclusive. This article will focus on the mechanisms of sorafenib, treatment and adverse reactions, to discuss the progression of sorafenib for the treatment of thyroid cancer.